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Vorapaxar is a first-in-class PAR-1 antagonistic drug based on the ent-himbacine scaffold. Detailed in 
this article are enantioselective and racemic routes to various novel vorapaxar analogues. Biological 
testing revealed these compounds to have moderate to excellent potencies against PAR-1 with the most 
potent analogue demonstrating an IC50 of 27 nM. 
Introduction 10 
The recent FDA approval of vorapaxar (Figure 1) for the 
“reduction of thrombotic cardiovascular events in patients with a 
history of myocardial infarction (MI) or peripheral arterial 
disease (PAD)” marked an exciting development in the blockade 
of thrombin induced cellular activities.1 Vorapaxar is a first-in-15 
class, highly potent protease activated receptor-1 (PAR-1) 
antagonist. PAR-1 is a seven transmembrane G-protein coupled 
receptor (7TM GPCR) expressed on many cell types throughout 
the body including platelets, endothelial cells and fibroblasts. It is 
agonised by an intramolecular mechanism following exposure to 20 
thrombin.2 It is an important receptor in the pathway towards 
thrombus formation and is associated with cardiovascular disease, 
as well as cancer and various fibrotic diseases.2 PAR-1 
antagonists could thus be used to treat a number of serious 
conditions. With this in mind, disclosed herein is the synthesis of 25 
a series of novel vorapaxar analogues with particular focus on 
functionalisation at a position that has not been explored 
previously, i.e. the C-9 position. 
 
Fig. 1 Structures of vorapaxar and himbacine 30 
Results and Discussion 
To begin, C-9-substituted vorapaxar analogues were to be 
synthesised on the basis of a published partial synthetic route 
towards natural product himbacine (Figure 1, and Schemes 1 & 
2).3-8 This route was designed to provide access to analogues that 35 
do not contain a carbamate group at C-7 and have a m-CF3 on the 
aryl group rather a m-F substituent. These alterations will not 
affect the activity of the antagonist to any significant degree since 
they themselves were relatively late stage pharmacokinetic-based 
decisions made during the development of vorapaxar that were 40 
shown to have little impact on potency, i.e. the carbamate was 
introduced as a means to improve oral delivery and the use of m-
F in place of m-CF3 was to reduce lipophilicity.
9 Moreover, the 
synthesis of analogues without these late stage changes, when 
trialling a new synthetic route to vorapaxar analogues, is if 45 
anything a more sensible choice as it allows for direct comparison 
with the larger body of literature compounds made in the earlier 
stages of the development of vorapaxar.9 Alteration(s) to the 
analogues described herein to aid pharmacokinetic properties 
without effecting potency can almost certainly be tuned into the 50 
core, if need be, at a later stage. 
 Initially, trans-methyl 2-(2-(tert-butoxy)-2-
oxoethyl)cyclohexanecarboxylate ((±)-1)4 and 5-methyl-2(5H)-
furanone (2)5 were synthesised using literature procedures. These 
were then reacted together using the conditions proposed by 55 
Casey et al. to give (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-
1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (3) and 
(3R,3aS,4S,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (4) via 
kinetic resolution, albeit in low yields (12% and 5% respectively) 60 
(Scheme 1).  
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Scheme 1 Stereoselective tricycle synthesis 
 In order to furnish the desired C-9 functionalised vorapaxar 
analogues, the tert-butyl group of compounds 3/4 had to be 
replaced with the biaryl motif that is essential for the PAR-1 5 
activity of vorapaxar.6 To set about this, initially the tert-butyl 
group of the higher yielding tricycle (3) was removed using 
TFA/CH2Cl2 (Scheme 2). The resulting acid was then coupled to 
ethanethiol using DCC and DMAP. The formed thioester (5) was 
next reduced using mild reducing conditions of triethylsilane and 10 
catalytic palladium on carbon to give an aldehyde (6).7 Finally, 
Horner-Emmons conditions were used for reaction with biaryl 
phosphonate ester 7, which was prepared according to a literature 
procedure,8 to form the desired C-9 functionalised vorapaxar 
analogues. Notably, prior to performing the Horner-Emmons 15 
reaction, the aldehyde underwent partial epimerisation at the C-4 
position. This conveniently afforded both C-4 epimers of the final 
C-9-keto-analogues (8 and 9, Scheme 2), and meant that the 
lower yielding tricycle 4 did not need to be carried through the 
synthesis to obtain compound 9. 20 
Scheme 2 Development of tricycle to give novel enantiomerically pure 
vorapaxar analogues 8 and 9 
 We noted from the outset that C-9-keto-analogues would have 
a useful carbonyl synthetic handle to allow the exploration of 25 
SAR in a direction as yet unexplored on vorapaxar. To the best of 
our knowledge, there are no vorapaxar analogues with 
substitution at the C-9 position. As an initial foray into the novel 
SAR possibilities, the ketone of compound 8 was reduced to an 
hydroxyl group using NaBH4 to give compounds 10 and 11 30 
(Figure 2) in 38% and 29% yield respectively. This was a 
significant transformation as it returned sp3 hybridisation at C-9, 
making the tricycle conformation more similar to that of 
vorapaxar. Additionally, compounds 8-11 would prove useful in 
exploring the effect on activity of sp2 vs. sp3 hybridisation at 35 
C-9. The stereochemical assignment of compounds 8-11 was 
made on the basis of 1H NMR coupling constants and 2D NMR 
analysis; see ESI for further details. 
 
Fig. 2 Novel enantiomerically pure vorapaxar analogues 10 and 11 40 
 Next we used commercially available 2-(5H)-furanone in place 
of methyl-furanone 2 for reaction with trans-methyl 2-(2-(tert-
butoxy)-2-oxoethyl)cyclohexanecarboxylate (±)-1 as a conduit to 
gain access to further distinct analogues of vorapaxar in terms of 
relative ring junction stereochemistry. The absence of the methyl 45 
group on 2-(5H)-furanone, and thus in subsequent vorapaxar 
analogues, would have no bearing as, in line with several 
examples in the literature, this methyl group is not thought to 
have an effect on PAR-1 antagonism.10 The reaction of (±)-1 and 
2-(5H)-furanone led to the formation of racemic compounds 50 
(±)-12 and (±)-13, which to our delight had distinct relative 
stereochemistries at C-9a/C-3a compared with C-8a/C-4a. For 
this reaction, the addition of KOt-Bu was not required for tricycle 
synthesis, which may have contributed to an increased overall 
yield of 51% for tricycle formation. 55 
 
Scheme 3 Racemic tricycle synthesis 
 The synthetic route detailed in Scheme 2 was next repeated on 
(±)-12 and (±)-13, which led to the formation of racemic PAR-1 
analogues (±)-14-16. The racemic compounds were easier to 60 
synthesise and use of (±)-12 and (±)-13 allowed access to PAR-1 
analogues with tricycle scaffolds with differing relative 
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stereochemical assignment at C-9a/C-3a compared with C-8a/C-
4a, i.e. (±)-14/15 and (±)-16, respectively. The enantiomeric pairs 
were then separated out into (+) and (–) enantiomers by chiral 
chromatography as the absolute stereochemistry of vorapaxar is 
believed to be important for PAR-1 potency.11  5 
 
Fig. 3 Racemic novel vorapaxar analogues (±)-14-16 
 The results of the synthetic efforts gave 10 key compounds 
which were tested in a biological assay to determine their potency 
against PAR-1 (Figures 2-5, Table 1). The assay was based on 10 
monitoring PAR-1 induced calcium flux in response to thrombin 
using FLIPR.12 The novel analogues showed concentration-
dependent antagonism in human lung fibroblasts vs. 10 nM 
thrombin as the agonist. The academic tool, RWJ-58259,13 was 
used as a positive control and for a potency comparator. 15 
 Enantiopure compounds 8-11 were tested initially (Figure 4). 
The most potent of these analogues, compound 9, gave an IC50 of 
0.5 µM. This meant that it had a similar potency to that of RWJ-
58259 (IC50 = 0.17 µM). Unfortunately, the potencies of the 
compounds did not quite match that of vorapaxar (IC50 = 13 nM, 20 
in this assay). It was interesting to note that the hydroxyl-
analogues (IC50: 10 = 72 µM and 11 = 120 µM) were less potent 
than the keto-analogues (IC50: 8 = 10.5 µM and 9 = 0.5 µM), 
indicating that the sp2 vs. sp3 hybridisation at C-9 was not critical 
to activity, and that (if anything) sp2 hybridisation may be 25 
moderately preferred. 
 
Fig. 4 The average (n = 6) percentage inhibition observed upon the 
addition of thrombin (10 nM) to human lung fibroblasts in buffer pre-
incubated with Fluo-4 NW dye mix and 0.003 - 300 µM antagonist; 30 
Compounds 8, 9, 10, 11 and RWJ-58259 
 Next, each of the enantiopure compounds obtained from (±)-
14-15, were tested. In all cases, the compounds failed to reach 
100% inhibition at a concentration of 30 µM. The concentration 
range was not extended to 300 µM, as seen with the compounds 35 
8-11, because solubility issues were starting to be observed at 30 
µM. As seen in the vorapaxar literature, one enantiomer was 
shown to be more potent than its pair (IC50: (-)-14 = 2.4 µM, (+)-
14 = 15 µM, (-)-15 = 0.1 µM and (+)-15 = 7.5 µM).11 In this 
series, the most potent compound (i.e. (-)-15) was slightly more 40 
potent than both compound 9 and RWJ-58259.‡  
 Finally, the analogues with distinct tricycle ring juncture 
stereochemistry, i.e. (+)-16 and (–)-16, were tested (Figure 5). 
The enantiomeric pair derived from compound 16 had vastly 
distinct potencies (Figure 5). Compound (-)-16 with an IC50 of 27 45 
nM was the most potent of all of the compounds tested. It was 
more potent than RWJ-58259 (IC50 = 170 nM, in this assay) and 
approached the potency of vorapaxar (IC50 = 13 nM). Conversely, 
its enantiomeric partner ((+)-16) gave a ca. 100-fold increase in 
IC50. This is one of the lowest potencies of the tested keto-50 
analogues and 1000 times less potent than vorapaxar.‡ 
 
Fig. 5 The average (n = 6) percentage inhibition observed upon the 
addition of thrombin (10 nM) to human lung fibroblasts in buffer pre-
incubated with Fluo-4 NW dye mix and 0.0003 - 30 µM antagonist; 55 
Compounds (+)-16, (-)-16 and RWJ-58259 
Table 1 IC50 values of vorapaxar, all vorapaxar analogues and RWJ-
58259 
Compound IC50 (µM)
a 
Vorapaxar 0.013 
8 10.5 
9 0.5 
10 72 
11 120 
(+)-14 15 
(-)-14 2.4 
(+)-15 7.5 
(-)-15 0.1 
(+)-16 13 
(-)-16 0.027 
RWJ-58259 0.17 
a See ESI for details on biological assay used to determine these values. 
Conclusions 60 
In conclusion, an enantioselective route to himbacine-like 
tricycles has been adapted and developed to give a number of 
novel vorapaxar analogues which were tested biologically. The 
nanomolar potency found with compound (–)-16 is very 
significant because the novel scaffold has the potential for further 65 
growth to investigate the SAR of vorapaxar, a first-in-class 
16 16 
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PAR-1 antagonist drug. Whilst there is excellent recent work on 
C-7-spirocyclic analogues of vorapaxar,14 and examples of 
functionalisation at other positions on the core, to the best of our 
knowledge these are the first PAR-1 active vorapaxar analogues 
with substitution at the C-9 position or with the differing relative 5 
stereochemistry on the tricycle. Consequently, especially with 
readily functionalisable groups at the C-9 position, there is the 
prospect of developing further novel and potent PAR-1 inhibitors 
which could be used for the treatment of cancer and various 
fibrotic diseases. 10 
Experimental section 
General Experimental 
All solvents employed in this study were reagent grade. All 
reagents were purchased from Sigma-Aldrich, UK and Alfa 
Aesar, UK and used as received unless otherwise stated. All 15 
reactions were magnetically stirred and monitored by thin layer 
chromatography (TLC) on pre-coated silica gel plates (254 μm) 
and/or by LCMS. Silica plates were initially examined under UV 
light and then developed using aqueous basic potassium 
permanganate stain. LCMS analysis was conducted on either 20 
System A, an Acquity UPLC BEH C18 column (2.1 mm × 50 
mm ID, 1.7 μm packing diameter) eluting with 0.1% formic acid 
in H2O (solvent A) and 0.1% formic acid in acetonitrile (MeCN) 
(solvent B), using the following elution gradient 0.0−1.5 min 
3−100% B, 1.5−1.9 min 100% B, 1.9−2.0 min 3% B, at a flow 25 
rate of 1 mL min−1 at 40 °C. The UV detection was an averaged 
signal from wavelength of 210 to 350 nm, and mass spectra were 
recorded on a mass spectrometer using alternate-scan electrospray 
positive and negative mode ionization (ES +ve and ES −ve); or 
System B, an Acquity UPLC BEH C18 column (50 mm × 2.1 30 
mm ID, 1.7 μm packing diameter) eluting with 10 mM 
ammonium bicarbonate ((NH4)HCO3) in H2O adjusted to pH10 
with ammonia solution (solvent A) and MeCN (solvent B) using 
the following elution gradient 0−1.5 min 1−97% B, 1.5−1.9 min 
97% B, 1.9−2.0 min 100% B at a flow rate of 1 mL min−1 at 40 35 
°C. Preperative TLC was carried out using 20 cm x 20 cm glass 
TLC plates with a silica gel 60 matrix, supplied by EMD/Merck 
KGaA. Flash chromatography was carried out with silica gel (33-
70 μm) supplied by Merck Co.. Automated column 
chromatography was performed using pre-packed silica gel 40 
columns on a Flashmaster II. The Flashmaster II is an automated 
multiuser flash chromatography system, available from Argonaut 
Technologies Ltd, which utilizes disposable, normal phase, SPE 
cartridges (2−100 g). Chiral column chromatography was 
performed using various columns and conditions, see below for 45 
details. Quoted yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. 1H 
NMR spectra were recorded at 600 MHz with a Bruker AMX600. 
13C NMR spectra were recorded at 150 MHz. Chemical shifts (δ 
values) are reported in parts per million (ppm) whilst coupling 50 
constants are reported in Hertz (Hz). 
 
trans-Methyl 2-(2-(tert-butoxy)-2-
oxoethyl)cyclohexanecarboxylate (1) 
n-BuLi (1.6 M in hexanes) (70.0 mL, 112 mmol) was added to a 55 
stirred solution of DIPA (15.7 mL, 112 mmol) in anhydrous THF 
(30 mL) at -78 °C, under Ar. The solution was stirred at -78 °C 
for 20 mins. A solution of tert-butyl acetate (15.0 mL, 112 mmol) 
was added and stirring continued for 30 min at -78 °C. Next, a 
solution of (E)-methyl 7-iodohept-2-enoate (13.7 g, 51 mmol) in 60 
anhydrous THF (15 mL) was added. The reaction mixture was 
stirred for a further 30 min at -78 °C. Finally, solid KOt-Bu (12.6 
g, 112 mmol) was added and stirring continued for a further 1 h at 
-78 °C. The reaction mixture was quenched with sat. aq. NH4Cl 
(100 mL) and diluted with H2O (50 mL). An extraction into 65 
EtOAc (2 x 100 mL) was completed and the combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to 
yield a crude pale yellow liquid. Multiple purifications by flash 
column chromatography (0-2% Et2O/CH2Cl2), (0-10% Et2O/Pet. 
Ether) and (0-2% Et2O/toluene) yielded trans-methyl 2-(2-(tert-70 
butoxy)-2-oxoethyl)cyclohexanecarboxylate (1) (3.1 g, 12 mmol, 
24%) as a colourless liquid; bp. 110-115 °C (at 2.1 mbar); 1H 
NMR (600 MHz, CDCl3) δ 3.66 (3H, s, COOCH3), 2.26 (1H, d, J 
= 10.9, CHHCOOtBu), 2.12 (1H, dt, J = 11.2, 3.6, C2H), 2.05-
1.98 (2H, m, C1H & CHHCOOtBu), 1.89 (1H, qd, J = 1.9, 13.2, 75 
C3HH), 1.84 (1H, dd, J = 2.1, 13.0, C6HH), 1.74 (1H, dtd, J = 
12.8, 3.4, 1.1, C4HH), 1.72-1.68 (1H, m, C5HH), 1.47 (1H, td, J = 
12.4, 2.6, C3HH), 1.43 (9H, s, C(CH3)3), 1.30 (1H, tq, J = 12.8, 
3.4, C5 HH), 1.21 (1H, tq, J = 13.2, 3.8, C4HH), 1.04 (1H, dq, J = 
13.2, 3.4, C6HH); 13C NMR (150 MHz, CDCl3) δ 176.1 80 
(COCOMe), 171.8 (COCOtBu), 80.4 (C(CH3)3), 51.7 (CH3), 49.0 
(C2H), 40.9 (CH2COO
tBu), 36.3 (C1H), 31.3 (C6H), 30.0 (C3H), 
28.2 (C(CH3)3), 25.5 (C
5H), 25.4 (C4H); IR (thin film) 2982 (C-
H), 2930 (C-H), 2854 (C-H), 1713 (C=O), 1451 (C-H), 1366 (C-
O), 1247 (C-O), 1151, 1108, 1025, 845 cm-1; m/z (ES+) 257 85 
(100%, [M+H]+); HRMS (CI) calcd for C13H11O3 [M-OMe]
+ 
225.14907, observed 225.14872. 
 
tert-Butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (3 and 4) 90 
n-BuLi (2.5 M in hexane) (3.60 ml, 9.00 mmol) was added 
dropwise to a stirred solution of freshly distilled TMP (1.54 mL, 
9.00 mmol) in anhydrous THF (10 mL) at -78 °C, under Ar. The 
solution was warmed to 0 °C and then re-cooled to -78 °C. A 
solution of trans-methyl 2-(2-(tert-butoxy)-2-95 
oxoethyl)cyclohexanecarboxylate (1) (1.10 g, 4.30 mmol) in 
anhydrous THF (5 mL) was added, dropwise, and stirring 
continued for 45 min at -78 °C. Next, a solution of 5-methyl-
2(5H)-furanone (2) (294 mg, 0.30 mmol) in anhydrous THF (5 
mL) was added, dropwise, and stirring continued for 1 h at -78 100 
°C. Finally, KOt-Bu (1.00 g, 9.00 mmol) was added. The reaction 
mixture was warmed to -40 °C, stirred for a further 3 h and then 
quenched with sat. aq. NH4Cl (20 mL). An extraction into EtOAc 
(2 x 40 mL) was done and the combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo to yield a 105 
crude yellow oily solid. Multiple purifications by flash column 
chromatography yielded  (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-
methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate 
(3) (117 mg, 0.36 mmol, 12%) and (3R,3aS,4S,4aR,8aR,9aS)-tert-
butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-110 
carboxylate (4) (47.5 mg, 0.15 mmol, 5%) as white solids. Data 
for (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (3): 1H 
NMR (600 MHz, CDCl3) δ 4.24 (1H, dd, J = 10.2, 6.0, C
3HMe), 
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3.77 (1H, d, J = 8.3, C9aH), 2.71-2.66 (1H, m, C8aH), 2.51 (1H, d, 
J = 4.9, C4H), 2.01-1.96 (1H, m, C8HH), 1.84-1.72 (4H, m, C4aH, 
C5HH, C6HH & C7HH), 1.50 (9H, s, C(CH3)3), 1.42 (3H, d, J = 
6.0, C3HCH3), 1.33-1.23 (2H, m, C
5HH & C8HH ), 1.22-1.14 
(2H, m, C6HH & C7HH); 13C NMR (150 MHz, CDCl3) δ 204.0 5 
(C9O), 172.0 (COOtBu), 171.1 (C1O), 82.5 (C(CH3)3), 77.6 
(C3HMe), 54.5 (C9aH), 48.4 (C3aH), 48.1 (C8aH), 44.1 (C4H), 
41.0 (C4aH), 31.4 (C5H2), 28.3 (C(CH3)3), 25.7 (C
8H2), 25.5 
(C6H2), 25.0 (C
7H2), 19.1 (C
3HCH3); IR (thin film) 2988 (C-H), 
2918 (C-H), 2855 (C-H), 1790 (C=O), 1727 (C=O), 1705 (C=O), 10 
1198 (C-O), 1197, 1133, 1061, 913, 835 cm-1; m/z (CI) 267 
(100%, [M-C4H9]
+); HRMS (CI) calcd for C18H27O5 [M+H]
+ 
323.1853, observed 323.1855. Data for (3R,3aS,4S,4aR,8aR,9aS)-
tert-butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (4): 1H NMR (600 MHz, CDCl3) δ 4.54 (1H, dq, J = 15 
10.2, 6.0, C3HMe), 3.48 (1H, d, J = 8.7, C9aH), 2.94 (1H, ddd, J = 
10.2, 8.7, 5.3, C3aH), 2.81 (1H, dd, J = 11.5, 5.3, C4H), 2.08 (1H, 
td, J = 11.8, 3.2, C8aH), 1.96-1.88 (3H, m, C4aH, C5HH & C8HH), 
1.84-1.80 (1H, m, C6HH), 1.75-1.71 (1H, m, C7HH), 1.48 (9H, s, 
C(CH3)3), 1.36 (3H, d, J = 6.0, C
3HCH3), 1.39-1.34 (1H, m, 20 
C8HH), 1.26-1.17 (2H, m, C6HH & C7HH), 1.13-1.05 (1H, m, 
C5HH); 13C NMR (150 MHz, CDCl3) δ 203.0 (C
9O), 171.6 
(COOtBu), 170.2 (C1O), 82.5 (C(CH3)3), 77.3 (C
3HMe), 56.3 
(C9aH), 52.4 (C8aH), 48.0 (C3aH & C4H), 41.5 (C4aH), 32.0 
(C5H2), 28.3 (C(CH3)3), 25.1 (C
8H2), 24.9 (C
6H2), 24.8 (C
7H2), 25 
20.3 (C3HCH3); IR (thin film) 2978 (C-H), 2933 (C-H), 2857 (C-
H), 1784 (C=O), 1717 (C=O), 1367, 1194 (C-O), 1146, 1066, 
985, 751 cm-1; m/z (CI) 267 (100%, [M-C4H9]
+); HRMS (CI) 
calcd for C18H27O5 [M+H]
+ 323.1853, observed 323.1856. 
 30 
(3R,3aS,4R,4aR,8aR,9aS)-3-Methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid 
TFA (0.5 mL) was added dropwise to a stirred solution of 
(3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (86.0 mg, 35 
0.27 mmol) in CH2Cl2 (0.5 mL) at 0 °C, under Ar. The reaction 
mixture was stirred at 20 °C for 16 h before being concentrated in 
vacuo. The residue was azeotroped with toluene to yield 
(3R,3aS,4R,4aR,8aR,9aS)-3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid (69.8 40 
mg, 0.26 mmol, 99%) as a white solid; 1H NMR (600 MHz, 
MeOH-d4) δ 4.39 (1H, td, J = 11.7, 6, C
3HMe), 3.82 (1H, d, J = 
8.7, C9aH), 2.87 (1H, dd, J = 10.4, 8.7, C3aH), 2.76 (1H, td, J = 
11.7, 3.4, C8aH), 2.71 (1H, d, J = 4.9, C4H), 1.97 (1H, dddd, J = 
12.4, 11.7, 4.9, 3.8, C4aH), 1.96-1.92 (1H, m, C8HH), 1.87-1.82 45 
(1H, m, C5HH), 1.81-1.74 (2H, m, C6HH & C7HH), 1.42 (3H, d, 
J = 6.0, C3HCH3), 1.40-1.36 (1H, m, C
5HH), 1.31-1.21 (3H, m, 
C6HH, C7HH & C8HH); 13C NMR (150 MHz, MeOH-d4) δ 206.3 
(C9O), 176.3 (COOH), 173.7 (C1O), 79.6 (C3HMe), 49.6 (C3aH), 
49.2 (C8aH), 49.0 (C9aH), 44.0 (C4H), 41.5 (C4aH), 32.5 (C5H2), 50 
26.7 (C8H2), 26.5 (C
6H2), 26.1 (C
7H2), 18.9 (C
3HCH3); IR (thin 
film) 2928 (C-H), 2859 (C-H), 1775 (C=O), 1702 (C=O), 1581, 
1416, 1201 (C-O), 1052 cm-1; m/z (EI) 267 (100%, [M+H]+); 
HRMS (EI) calcd for C14H18O5 [M+H]
+ 266.1149, observed 
266.1150. 55 
 
 
 
(3R,3aR,4R,4aR,8aR,9aS)-S-Ethyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (5) 60 
DCC (149 mg, 0.72 mmol) was added to a stirred solution of 
(3R,3aS,4R,4aR,8aR,9aS)-3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid (160 
mg, 0.60 mmol), ethanethiol (173 µL, 2.40 mmol) and DMAP 
(37.0 mg, 0.30 mmol) in CH2Cl2 (5 mL) at 0 °C, under Ar. The 65 
reaction mixture was stirred at 20 °C for 16 h before being 
filtered under vacuum to remove the precipitate. The filtrate was 
concentrated in vacuo to yield a crude colourless oil. Purification 
by flash column chromatography (0-2% Et2O/CH2Cl2) yielded 
(3R,3aR,4R,4aR,8aR,9aS)-S-ethyl 3-methyl-1,9-70 
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (5) (128 
mg, 0.41 mmol, 69%) as a white solid; Rf 0.64 (8% 
Et2O/CH2Cl2); 
1H NMR (600 MHz, CDCl3) δ 4.24 (1H, dq, J = 
10.5, 6.0, C3HMe), 3.73 (1H, d, J = 8.7, C9aH), 2.96 (1H, q, J = 
6.5, SCHHCH3), 2.92 (1H, q, J = 6.5, SCHHCH3), 2.84 (1H, td, J 75 
= 11.9, 3.4, C8aH), 2.75 (1H, d, J = 4.5, C4H), 2.65 (1H, dd, J = 
10.5, 8.7, C3aH), 2.00-1.95 (1H, m, C8HH), 1.86-1.74 (4H, m, 
C4aH, C5HH, C6HH & C7HH), 1.44 (3H, d, J = 6.0, C3HCH3), 
1.40-1.32 (1H, m, C5HH), 1.30 (3H, t, J = 7.3, SCH2CH3), 1.28-
1.11 (3H, m, C6HH, C7HH & C8HH); 13C NMR (150 MHz, 80 
CDCl3) δ 203.8 (C
9O), 200.3 (COSEt), 170.7 (C1O), 77.3 
(C3HMe), 54.7 (C9aH), 50.6 (C4H), 48.8 (C8aH), 48.3 (C3aH), 
41.8 (C4aH), 31.4 (C5H2), 25.7 (C
8H2), 25.3 (C
6H2), 24.8 (C
7H2), 
24.1 (CH2CH3), 18.9 (C
3HCH3), 14.6 (CH2CH3); IR (thin film) 
2930 (C-H), 2854 (C-H), 1785 (C=O), 1708 (C=O), 1672, 1197 85 
(C-O), 1059, 958 cm-1; m/z (EI) 252 (100%, [M-SEt-Me+OH]+); 
HRMS (EI) calcd for C16H22O4S [M+H]
+ 310.1233, observed 
310.1233. 
 
(3R,3aS,4aS,8aR,9aS)-3-Methyl-1,9-90 
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (6) 
Triethylsilane (263 µL, 1.65 mmol) was added to a stirred 
suspension of (3R,3aR,4R,4aR,8aR,9aS)-S-ethyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (5) (128 
mg, 0.41 mmol), palladium on carbon (10%) (44.0 mg, 0.04 95 
mmol) and MgSO4 (to dry) in degassed acetone (5 mL) under Ar. 
The reaction mixture was stirred at 20 °C for 16 h before it was 
filtered over celite and concentrated in vacuo. Purification by 
flash column chromatography (0-2% Et2O/CH2Cl2) gave partial 
racemisation at C4 to yield (3R,3aS,4aS,8aR,9aS)-3-methyl-1,9-100 
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (6) 
(4S:4R; 1:0.16) (50 mg, 0.20 mmol, 48%) as a colourless film; Rf 
0.44 (8% Et2O/CH2Cl2); 
1H NMR (600 MHz, CDCl3) δ 10.14 
(1H, s, 4S-CHO), 4.29 (1H, dq, J = 10.2, 6.0, 4S-C3HMe), 3.67 
(1H, d, J = 8.7, 4S-C9aH), 2.88 (1H, dd, J = 10.2, 8.7, 4S-C3aH), 105 
2.80 (1H, d, J = 4.9, 4S-C4H), 2.20 (1H, ddd, J = 12.4, 12.0, 3.4, 
4S-C8aH), 2.09-1.96 (3H, m, 4S-C4aH, 4S-C5HH & 4S-C8HH), 
1.88-1.81 (2H, m, 4S-C6HH & 4S-C7HH), 1.68 (1H, qd, J = 12.4, 
3.4, 4S-C5HH), 1.42 (3H, d, J = 6.0, C3HCH3), 1.36-1.32 (1H, m, 
4S-C8HH), 1.23-1.17 (2H, m, 4S-C6HH & 4S-C7HH); 13C NMR 110 
(150 MHz, CDCl3) δ 202.8 (4S-C
9O), 202.7 (4S-CHO), 170.5 
(4S-C1O), 77.2 (4S-C3HMe), 54.5 (4S-C9aH), 49.4 (4S-C8aH), 
49.1 (4S-C4H), 44.9 (4S-C3aH), 41.6 (4S-C4aH), 30.7 (4S-C5H2), 
26.0 (4S-C8H2), 25.3 (4S-C
6H2), 24.8 (4S-C
7H2), 19.1 (4S-
C3HCH3). 115 
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(3R,3aS,4aS,8aR,9aS)-3-Methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (8 
and 9) 
n-BuLi (1.6 M in hexanes) (150 µL, 0.24 mmol) was added 5 
dropwise to a stirred solution of diethyl (5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (7) (75 
mg, 0.20 mmol) in anhydrous THF (1 mL) at 0 °C, under Ar. The 
solution was stirred at 0 °C for 10 min before 
(3R,3aS,4aS,8aR,9aS)-3-methyl-1,9-10 
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (6) (50 
mg, 0.20 mmol) was added. The reaction mixture was stirred at 0 
°C for 45 min and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into EtOAc (10 mL) was done and the organic layer 
was dried (MgSO4), filtered and concentrated in vacuo to yield a 15 
crude yellow oil. Purification by flash column chromatography 
(0-15% Et2O/CH2Cl2) and then (20-35% Et2O/toluene) yielded 
(3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (8) 20 
(39 mg, 0.083 mmol, 41%) and (3R,3aS,4S,4aS,8aR,9aS)-3-
methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (9) 
(14 mg, 0.03 mmol, 15%) as white solids. Data for 
(3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-25 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (8): 
[α]D
20 = +14 (MeOH); 1H NMR (600 MHz, CDCl3) δ 8.82 (1H, d, 
J = 2.3, CHN), 7.89 (1H, dd, J = 8.3, 2.3, CHCCHN), 7.82 (1H, s, 
CHCCF3), 7.78 (1H, d, J = 7.5, CHCCHCCF3), 7.68 (1H, d, J = 30 
7.5, CHCHCCF3), 7.62 (1H, t, J = 7.9, CHCHCCF3), 7.35 (1H, d, 
J = 7.9, CHCN), 7.10 (1H, dd, J = 15.4, 9.8, C4HCHCHPyr), 6.66 
(1H, d, J = 15.4, C4HCHCHPyr), 4.42 (1H, dq, J = 10.2, 6, 
C3HMe), 3.66 (1H, d, J = 8.7, C9aH), 2.71 (1H, dd, J = 10.2, 8.7, 
C3aH), 2.59 (1H, dd, J = 9.6, 4.0, C4H), 2.44 (1H, td, J = 12.0, 35 
3.6, C8aH), 2.05-1.99 (1H, m, C8HH), 1.88 (1H, tt, J = 12.3, 4, 
C4aH), 1.82-1.77 (1H, m, C7HH), 1.77-1.72 (1H, m, C6HH), 1.71-
1.66 (1H, m, C5HH), 1.48 (3H, d, J = 6.0, C3HCH3), 1.46-1.40 
(1H, m, C5HH), 1.40-1.34 (1H, m, C8HH), 1.23-1.17 (2H, m, 
C6HH & C7HH); 13C NMR (150 MHz, CDCl3) δ 203.8 (C
9O), 40 
170.9 (C1O), 154.0 (CN), 148.3 (CHN), 138.4 (CCHCCF3), 135.3 
(CHCCHN), 134.2 (CCHN), 132.8 (C4HCHCHPyr), 132.4 
(C4HCHCHPyr), 131.7 (q, J = 32.8, CCF3), 130.3 
(CHCCHCCF3), 129.8 (CHCHCCF3), 125.0 (q, J = 4.0, 
CHCHCCF3), 123.8 (q, J = 4.0, CCHCCF3), 122.3 (d, J = 247.6, 45 
CF3), 122.3 (CHCN), 78.0 (C
3HMe), 54.1 (C9aH), 51.8 (C3aH), 
48.3 (C8aH), 42.2 (C4aH), 41.1 (C4H), 31.8 (C5H2), 25.5 (C
6H2), 
25.4 (C8H2), 24.9 (C
7H2), 19.2 (C
3HCH3); IR (thin film) 2921 (C-
H), 2852 (C-H), 1783 (C=O), 1719 (C=O), 1447, 1335, 1265, 
1167 (C-O), 1127, 804, 730 cm-1; m/z (ES+) 470 (100%, 50 
[M+H]+); HRMS (ES+) calcd for C27H27NO3F3 [M+H]
+ 
470.1943, observed 470.1920. Data for (3R,3aS,4S,4aS,8aR,9aS)-
3-methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (9): 
1H NMR (600 MHz, CDCl3) δ 8.80 (1H, d, J = 2.4, CHN), 7.87 55 
(1H, dd, J = 8.1, 2.4, CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 
(1H, d, J = 7.9, CHCCHCCF3), 7.67 (1H, d, J = 7.9, 
CHCHCCF3), 7.61 (1H, t, J = 7.9, CHCHCCF3), 7.31 (1H, d, J = 
8.1, CHCN), 6.66 (1H, d, J = 15.4, C4HCHCHPyr), 6.60 (1H, dd, 
J = 15.4, 9.4, C4HCHCHPyr), 4.57 (1H, dq, J = 9.4, 6.0, C3HMe), 60 
3.58 (1H, d, J = 7.9, C9aH), 2.90-2.83 (2H, m, C3aH & C4H), 2.18 
(1H, td, J = 11.6, 3.2, C8aH), 1.99-1.92 (2H, m, C5HH & C8HH), 
1.86-1.81 (1H, m, C6HH), 1.78-1.69 (2H, m, C4aH & C7HH), 1.44 
(3H, d, J = 6.0, C3HCH3), 1.42-1.38 (1H, m, C
8HH), 1.24-1.16 
(2H, m, C6HH & C7HH), 1.11-1.01 (1H, m, C5HH); 13C NMR 65 
(150 MHz, CDCl3) δ 203.9 (C
9O), 170.8 (C1O), 153.9 (CN), 
148.4 (CHN), 138.5 (CCHCCF3), 135.2 (CHCCHN), 134.5 
(C4HCHCHPyr), 134.1 (CCHN), 131.9 (C4HCHCHPyr), 131.7 
(q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 
124.9 (q, J = 3.8, CHCHCCF3), 123.8 (q, J = 3.8, CCHCCF3), 70 
124.1 (d, J = 271.7, CF3), 122.0 (CHCN), 77.3 (C
3HMe), 56.7 
(C9aH), 53.1 (C8aH), 52.5 (C3aH), 45.5 (C4H), 43.3 (C4aH), 33.1 
(C5H2), 25.3 (C
6H2), 25.0 (C
8H2), 24.8 (C
7H2), 21.9 (C
3HCH3); 
IR (thin film) 2922 (C-H), 2855 (C-H), 1781 (C=O), 1714 (C=O), 
1440, 1335, 1268, 1123 (C-O), 1074, 810, 703 cm-1; m/z (EI) 469 75 
(100%, [M]+); HRMS (EI) calcd for C27H26NO3F3 [M]
+ 469.1859, 
observed 469.1859. 
 
(3R,3aS,4R,4aS,8aR,9aS)-9-Hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-80 
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (10 and 11) 
NaBH4 (2.13 mg, 0.06 mmol) was added to a stirred solution of 
(3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (8) 85 
(24.0 mg, 0.05 mmol) in anhydrous THF (2 mL) and MeOH (2 
mL) at 0 °C, under Ar. The reaction mixture was stirred at 0 °C 
for 15 min and then quenched with sat. aq. NH4Cl (0.5 mL). An 
extraction into Et2O (5 mL) was done and the organic layer was 
dried (MgSO4), filtered and concentrated in vacuo to yield a 90 
crude yellow gum. Purification by flash column chromatography 
(0-2% Et2O/CH2Cl2) yielded (3R,3aS,4R,4aS,8aR,9R,9aS)-9-
hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one as a mixture of 95 
isomers. Purification by preparative thin layer chomatography (0-
2% Et2O/CH2Cl2) yielded (3R,3aS,4R,4aS,8aR,9R,9aS)-9-
hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (10) (9 mg, 100 
0.02 mmol, 38%) and (3R,3aS,4R,4aS,8aR,9S,9aS)-9-hydroxy-3-
methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (11) (7 mg, 
0.02 mmol, 29%) as white solids. Data for 
(3R,3aS,4R,4aS,8aR,9R,9aS)-9-hydroxy-3-methyl-4-((E)-2-(5-(3-105 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (10): 1H NMR 
(600 MHz, CDCl3) δ 8.80 (1H, d, J = 1.9, CHN), 7.86 (1H, dd, J 
= 8.1, 1.9, CHCCHN), 7.82 (s1H,, CHCCF3), 7.77 (1H, d, J = 
7.5, CHCCHCCF3), 7.66 (1H, d, J = 7.5, CHCHCCF3), 7.61 (1H, 110 
t, J = 7.9, CHCHCCF3), 7.35 (1H, d, J = 8.1, CHCN), 6.88 (1H, 
dd, J = 15.4, 9.8, C4HCHCHPyr), 6.55 (1H, d, J = 15.4, 
C4HCHCHPyr), 4.54 (1H, dq, J = 10.4, 6.0, C3HMe), 3.47 (1H, 
ddd, J = 10.9, 9.8, 1.1, C9HOH), 2.74 (1H, dd, J = 9.8, 7.9, C9aH), 
2.54 (1H, d, J = 1.9, OH),  2.40 (1H, dd, J = 9.6, 4.0, C4H), 2.36-115 
2.30 (2H, m, C3aH & C8HH), 1.78-1.72 (2H, m, C6HH & C7HH), 
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1.58-1.49 (3H, m, C4aH, C5HH & C8aH), 1.47 (1H, d, J = 6.0, 
C3HCH3),1.32-1.16 (4H, m, C
5HH, C6HH, C7HH & C8HH); 13C 
NMR (150 MHz, CDCl3) δ 177.9 (C
1O), 154.6 (CN), 148.1 
(CHN), 131.8 (CCHCCF3), 131.5 (CHCCHN), 131.3 
(C4HCHCHPyr), 130.9 (q, J = 32.1, CCF3),  130.3 5 
(C4HCHCHPyr & CHCCHCCF3), 129.9 (CCHN), 129.8 
(CHCHCCF3), 124.9 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, 
CCHCCF3), 124.1 (d, J = 272.1, CF3), 121.6 (CHCN), 78.5 
(C3HMe), 73.2 (C9HOH), 49.5 (C3aH), 47.7 (C9aH), 41.1 (C4H), 
40.2 (C4aH), 38.7 (C8aH), 32.1 (C5H2), 31.2 (C
8H2), 26.1 (C
6H2) 10 
25.5 (C7H2), 19.5 (C
3HCH3); IR (thin film) 2921 (C-H), 2851 (C-
H), 1764 (C=O), 1440, 1334, 1267, 1166 (C-O), 1124, 1075, 
1051, 804, 755 cm-1; m/z (ES+) 472 (100%, [M]+); HRMS (EI) 
calcd for C27H28NO3F3 [M-H]
+ 471.2016, observed 471.2016. 
Data for (3R,3aS,4R,4aS,8aR,9S,9aS)-9-hydroxy-3-methyl-4-((E)-15 
2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (11): 1H NMR 
(600 MHz, CDCl3) δ 8.79 (1H, d, J = 1.9, CHN), 7.85 (1H, dd, J 
= 8.1, 1.9, CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 (1H, d, J = 
7.5, CHCHCCF3), 7.66 (1H, d, J = 7.5, CHCCHCCF3), 7.61 (1H, 20 
t, J = 7.9, CHCHCCF3), 7.32 (1H, d, J = 8.3, CHCN), 6.87 (1H, 
dd, J = 15.4, 10.2, C4HCHCHPyr), 6.52 (1H, d, J = 15.4, 
C4HCHCHPyr), 4.74 (1H, dq, J = 10.5, 6.0, C3HMe), 4.09 (1H, 
td, J = 4.9, 2.3, C9H), 2.93 (1H, dd, J = 8.3, 4.9, C9aH), 2.48 (1H, 
dd, J = 10.2, 4.2, C4H), 2.21 (1H, dd, J = 10.5, 8.3, C3aH), 2.11 25 
(1H, d, J = 4.9, OH), 1.92 (1H, tt, J = 11.7, 4.5, C4aH), 1.78-1.70 
(2H, m, C6HH & C7HH), 1.59-1.54 (3H, m, C5HH, C8HH & 
C8aH), 1.51-1.44 (1H, m, C8HH), 1.44 (3H, d, J = 6.0, C3HCH3), 
1.31-1.19 (3H, m, C5HH, C6HH & C7HH); 13C NMR (150 MHz, 
CDCl3) δ 177.4 (C
1O), 154.7 (CN), 148.1 (CHN), 138.6 30 
(CCHCCF3), 135.4 (C
4HCHCHPyr), 135.1 (CHCCHN), 133.7 
(CCHN), 131.7 (q, J = 32.1, CCF3), 130.8 (C
4HCHCHPyr), 130.3 
(CHCCHCCF3), 129.8 (CHCHCCF3), 124.8 (q, J = 4.0, 
CHCHCCF3), 123.8 (q, J = 4.0, CCHCCF3), 124.1 (d, J = 271.7, 
CF3), 121.9 (CHCN), 79.7 (C
3HMe), 69.0 (C9HOH), 48.4 (C3aH), 35 
45.8 (C9aH), 41.3 (C4H), 38.4 (C8aH2), 31.7 (C
4aH), 31.4 (C5H2), 
28.9 (C8H2), 26.4 (C
6H2), 26.1 (C
7H2), 19.3 (C
3HCH3); IR (thin 
film) 2924 (C-H), 2853 (C-H), 1761 (C=O), 1440, 1334, 1267, 
1165 (C-O), 1124, 1075, 1050, 803, 700 cm-1; m/z (ES+) 472 
(100%, [M]+); HRMS (ES+) calcd for C27H29NO3F3 [M]
+ 40 
472.2100, observed 472.2089. 
 
rac-tert-Butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (12 and 13) 
n-BuLi (2.7 M in heptanes) (12.8 mL, 34.5 mmol) was added 45 
dropwise to a stirred solution of freshly distilled TMP (5.87 mL, 
34.5 mmol) in anhydrous 2-MeTHF (40 mL) at -78 °C, under N2. 
The solution was warmed to 0 °C and then re-cooled to -78 °C. A 
solution of trans-methyl 2-(2-(tert-butoxy)-2-
oxoethyl)cyclohexanecarboxylate (1) (4.21 g, 16.4 mmol) in 50 
anhydrous 2-MeTHF (40 mL) was added dropwise and stirring 
continued for 30 min at -78 °C. Next, furan-2(5H)-one (0.58 mL, 
8.21 mmol) was added dropwise. The reaction mixture was 
stirred for a further 3 h, quenched with sat. aq. NH4Cl (50 mL) 
and diluted with H2O (25 mL). An extraction into EtOAc (2 x 50 55 
mL) was done and the combined organic layers were washed with 
brine (30 mL), dried (hydrophobic frit) and concentrated in vacuo 
to yield a crude yellow oil with white precipitate. Purification by 
automated column chromatography (0-100% 
EtOAc/cyclohexane) yielded (3aS*,4R*,4aS*,8aS*,9aS*)-tert-60 
butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate 
(13) (663 mg, 2.15 mmol, 26%) and (3aS*,4R*,4aR*,8aR*,9aS*)-
tert-butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (12) (644 mg, 2.09 mmol, 25%) as white solids. Data 
for (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-65 
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (13): 1H 
NMR (600 MHz, CDCl3) δ 
1H NMR (600 MHz, CDCl3)  4.22 
(1H, d, J = 3.8, C3HH), 4.21 (1H, s, C3HH),  3.49 (1H, d, J = 7.5, 
C9aH), 3.15 (1H, ddd, J = 11.5, 7.5, 3.8, C3aH), 2.41 (1H, t, J = 
11.5, C4H), 2.14-2.10 (1H, m, C8HH), 1.99 (1H, ddd, J = 12.0, 70 
10.7, 3.6, C8aH), 1.82-1.66 (4H, m, C4aH, C5HH, C6HH & 
C7HH), 1.48 (9H, s, C(CH3)3), 1.46-1.41 (1H, m, C
8HH), 1.25-
1.12 (3H, m, C5HH, C6HH & C7HH); 13C NMR (150 MHz, 
CDCl3)  201.9 (C
9O), 172.4 (COOtBu), 171.5 (C1O), 82.5 
(C(CH3)3), 70.5 (C
3H2), 53.3 (C
9aH), 51.3 (C8aH), 51.0 (C4H), 75 
42.8 (C4aH), 42.8 (C3aH), 31.5 (C8H2), 28.2 (C(CH3)3), 25.1 
(C5H2), 25.0 (C
6H2), 24.8 (C
7H2); IR (thin film) 2974 (C-H), 
2929 (C-H), 2856 (C-H), 1795 (C=O), 1715 (C=O), 1367 (C-H), 
1244 (C-O), 1157, 1021, 845 cm-1; m/z (ES+) 326 (100%, 
M[NH4
+]+); HRMS (EI) calcd for C17H24O5 [M+H]
+ 308.1618, 80 
observed 308.1613. Data for (3aS*,4R*,4aR*,8aR*,9aS*)-tert-
butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate 
(12): 1H NMR (600 MHz, CDCl3) δ 4.39 (1H, t, J = 8.3, C
3HH), 
3.94 (1H, t, J = 9.8, C3HH), 3.72 (1H, d, J = 8.7, C9aH), 3.25 (1H, 
ddd, J = 9.8, 8.7, 8.3, C3aH), 2.66 (1H, td, J = 12.0, 3.6, C8aH), 85 
2.53 (1H, d, J = 4.5, C4H), 2.03 (1H, d, J = 14.7, C8HH), 1.85 
(1H, tdd, J = 12.0, 4.5, 3.4, C4aH), 1.84-1.76 (3H, m, C5HH, 
C6HH & C7HH), 1.50 (9H, s, C(CH3)3), 1.49-1.42 (1H, m, 
C8HH), 1.36-1.15 (3H, m, C5HH, C6HH & C7HH); 13C NMR 
(150 MHz, CDCl3)  203.8 (C
9O), 172.0 (COOtBu), 171.8 (C1O), 90 
82.5 (C(CH3)3), 69.5 (C
3H2), 52.9 (C
9aH), 48.2 (C8aH), 44.9 
(C4H), 40.6 (C4aH), 40.3 (C3aH), 31.4 (C8H2), 28.3 (C(CH3)3), 
25.9 (C5H2), 25.7 (C
6H2), 25.1 (C
7H2); IR (thin film) 2926 (C-H), 
2850 (C-H), 1778 (C=O), 1715 (C=O), 1698 (C=O), 1365 (C-H), 
1204 (C-O), 1138, 1002, 845 cm-1; m/z (ES+) 326 (100%, 95 
[M+NH4]
+); HRMS (ES-) calcd for C17H23O5 [M-H]
+ 307.1545, 
observed 307.1546. 
 
(3aS*,4R*,4aR*,8aR*,9aS*)-1,9-
Dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid 100 
TFA (0.3 mL) was added dropwise to a stirred solution of 
(3aS*,4R*,4aR*,8aR*,9aS*)-tert-butyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (13) (50.0 
mg, 0.16 mmol) in anhydrous CH2Cl2 (0.3 mL)  at 0 °C, under 
Ar. The reaction mixture was stirred at 20 °C for 16 h before 105 
being concentrated in vacuo. The residue was azeotroped with 
toluene to yield (3aS*,4R*,4aR*,8aR*,9aS*)-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid (40.0 
mg, 0.16 mmol, 99%) as a white solid; 1H NMR (600 MHz, 
MeOH-d4) δ 4.43 (1H, dd, J = 9.2, 8.3, C
3HH), 4.05 (1H, dd, J = 110 
9.8, 9.2, C3HH), 3.75 (1H, d, J = 9.0, C9aH), 3.37 (1H, ddd, J = 
9.8, 9.0, 8.3, C3aH), 2.72 (1H, d, J = 4.9, C4H), 2.69-2.64 (1H, m, 
C8aH), 1.98-1.95 (1H, m, C8HH), 1.98 (1H, dddd, J = 13.2, 12.0, 
4.9, 3.0, C4aH), 1.87-1.82 (1H, m, C5HH), 1.82-1.75 (2H, m, 
C6HH & C7HH), 1.44-1.35 (1H, m, C5HH), 1.32-1.21 (3H, m, 115 
C6HH, C7HH & C8HH); 13C NMR (150 MHz, MeOH-d4) δ 206.3 
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(C9O), 176.4 (COOH), 174.6 (C1O), 71.3 (C3H2), 54.1 (C
9aH), 
49.4 (C8aH), 44.9 (C4H), 41.2 (C3aH), 41.0 (C4aH), 32.5 (C5H2), 
27.0 (C8H2), 26.7 (C
6H2), 26.3 (C
7H2); IR (thin film) 2936 (C-H), 
2857 (C-H), 1759 (C=O), 1701 (C=O), 1170, 1000, 839, 800, 
719, 645, 549 cm-1; m/z (ES+) 253 (100%, [M+H]+); HRMS (ES-5 
) calcd for C13H15O5 [M-H]
+ 251.0920, observed 251.0919. 
(3aR*,4R*,4aR*,8aR*,9aS*)-S-ethyl 1,9-
Dioxododecahydronaphtho[2,3-c]furan-4-carbothioate 
DCC (29.7 mg, 0.14 mmol) was added to a stirred solution of 
(3aS*,4R*,4aR*,8aR*,9aS*)-1,9-dioxododecahydronaphtho[2,3-10 
c]furan-4-carboxylic acid (30.0 mg, 0.12 mmol), ethanethiol 
(26.0 µL, 0.36 mmol) and DMAP (7.00 mg, 0.06 mmol) in DMF 
(1 mL) at 0 °C, under Ar. The reaction mixture was stirred at 20 
°C for 2 h before being diluted with CH2Cl2 (10 mL) and washed 
with H2O (2 x 5 mL). The organic layer was dried (MgSO4), 15 
filtered and concentrated in vacuo to yield a crude pink solid. 
Purification by column chromatography (0-50% Et2O/Pet. Ether) 
yielded (3aR*,4R*,4aR*,8aR*,9aS*)-S-ethyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (10.5 mg, 
0.035 mmol, 29%) as a white solid; 1H NMR (600 MHz, CDCl3) 20 
δ 4.38 (1H, dd, J = 9.0, 8.1, C3HH), 3.93 (1H, dd, J = 10.8, 9.0, 
C3HH), 3.68 (1H, d, J = 8.7, C9aH), 3.19 (1H, ddd, J = 10.9, 8.7, 
8.1, C3aH), 2.94 (2H, qd, J = 7.5, 2.6, CH2CH3), 2.79 (1H, td, J = 
12.2, 12.0, 3.8, C8aH), 2.78 (1H, d, J = 4.5, C4H), 2.02-1.97 (1H, 
m, C8HH), 1.87 (1H, dddd, J = 12.2, 12.0, 4.5, 3.8, C4aH), 1.83-25 
1.75 (3H, m, C5HH, C6HH & C7HH), 1.40-1.32 (1H, m, C8HH), 
1.30 (3H, t, J = 7.5, CH2CH3), 1.28-1.21 (1H, m, C
5HH), 1.21-
1.15 (2H, m, C6HH & C7HH); 13C NMR (150 MHz, CDCl3) δ 
203.7 (C9O), 200.4 (COSEt), 171.5 (C1O), 69.1 (C3H2), 53.1 
(C9aH), 51.4 (C4H), 48.4 (C8aH), 41.2 (C4aH), 40.7 (C3aH), 31.5 30 
(C5H2), 25.7 (C
8H2), 25.6 (C
6H2), 24.8 (C
7H2), 24.1 (CH2CH3), 
14.6 (CH2CH3); IR (thin film) 2931 (C-H), 2887 (C-H), 1793 
(C=O), 1708 (C=O), 1672 (C=O), 1203, 1137, 982, 897 cm-1; m/z 
(ES+) 297 (100%, [M+H]+); HRMS (ES-) calcd for C15H19O4S 
[M-H]+ 295.1003, observed 295.1004. 35 
 
rac-(3aS,4aS,8aR,9aS)-1,9-Dioxododecahydronaphtho[2,3-
c]furan-4-carbaldehyde 
Triethylsilane (15 µL, 0.09 mmol) was added to a stirred 
suspension of rac-(3aR,4R,4aR,8aR,9aS)-S-ethyl 1,9-40 
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (10.0 mg, 
0.03 mmol), palladium on carbon (10%) (4.00 mg, 0.003 mmol) 
in degassed acetone (0.2 mL). The reaction mixture was stirred at 
20 °C for 16 h before being filtered through celite and the filtrate 
concentrated in vacuo. Purification by flash column 45 
chromatography (0-2% Et2O/CH2Cl2) gave partial racemisation at 
C4 to yield rac-(3aS,4aS,8aR,9aS)-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (4S:4R; 
0.7:1) (7.00 mg, 0.03 mmol, 99%) as a white solid; 1H NMR (600 
MHz, CDCl3) δ 10.11 (1H, s, 4S-CHO), 9.90 (1H, d, J = 1.5, 4R-50 
CHO), 4.47-4.44 (1H, m, 4R-C3HH), 4.38 (1H, dd, J = 9.0, 7.9, 
4S-C3HH), 4.04-3.96 (2H, m, 4R-C3HH & 4S-C3HH), 3.61 (1H, 
d, J = 9.0, 4S-C9aH), 3.47-3.40 (3H, m, 4R-C9aH, 4R-C3aH & 4S-
C3aH), 3.09 (1H, dd, J = 11.7, 3.0, 4R-C4H), 2.83 (1H, d, J = 4.5, 
4S-C4H),  2.22 (1H, td, J = 11.7, 3.4, 4R-C8aH), 2.17 (1H, td, J = 55 
11.7, 3.8, 4S-C8aH), 2.11-1.94 (6H, m, 4R-C4aH, 4S-C4aH, 4R-
C7HH, 4S-C7HH, 4R-C8HH & 4S-C8HH), 1.90-1.74 (3H, m, 4R-
C5HH, 4R-C7HH & 4S-C7HH),  1.71-1.63 (1H, m, 4S-C5HH), 
1.47-1.39 (1H, m, 4R-C8HH), 1.37-1.15 (7H, m, 4R-C5HH, 4S-
C5HH, 4R-C6HH, 4S-C6HH, 4R-C7HH, 4S-C7HH & 4S-C8HH); 60 
13C NMR (150 MHz, CDCl3) δ 202.8 (4S-C
9O), 202.8 (4R-C9O), 
202.6 (4R-CHO), 201.3 (4S-CHO), 171.4 (4R-C1O), 171.0 (4S-
C1O), 69.4 (4R-C3H2), 68.0 (4S-C
3H2), 54.0 (4S-C
9aH), 52.9 (4S-
C4H), 52.9 (4R-C9aH), 52.6 (4S-C8aH), 50.0 (4R-C4H), 49.4 (4R-
C8aH), 41.0 (4R-C4aH), 40.2 (4S-C4aH), 39.0 (4S-C3aH), 36.8 (4R-65 
C3aH), 32.0 (4S-C5H2), 30.6 (4R-C
5H2), 26.0 (4R-C
8H2), 25.7 (4S-
C8H2), 24.9 (4S-C
6H2 & 4R-C
6H2), 24.8 (4R-C
7H2), 24.6 (4S-
C7H2); IR (thin film) 2928 (C-H), 2858 (C-H), 1779 (C=O), 1705 
(C=O), 1208, 1165, 1120, 1016, 750 cm-1; m/z (ES+) 237 (100%, 
[M+H]+); HRMS (EI) calcd for C13H16O4 [M-H]
+ 236.1043, 70 
observed 236.1044. 
 
rac-(3aS,4aS,8aR,9aS)-4-((E)-2-(5-(3-
(Trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (14 75 
and 15) 
n-BuLi (1.6 M in hexanes) (144 µL, 0.23 mmol) was added 
dropwise to a stirred solution of diethyl ((5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)methyl)phosphonate (7) 
(79.0 mg, 0.21 mmol) in anhydrous THF (1 mL) at 0 °C, under 80 
Ar. The solution was stirred at 0 °C for 10 min before a solution 
of rac-(3aS,4aS,8aR,9aS)-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carbaldehyde (50 mg, 0.21 mmol) in anhydrous THF (1 
mL) was added. The reaction mixture was stirred at 0 °C for 45 
min and then quenched with sat. aq. NH4Cl (10 mL). An 85 
extraction into EtOAc (2 x 5 mL) was done and the combined 
organic layers were dried (MgSO4), filtered and concentrated in 
vacuo to yield a crude yellow gum. Purification by flash column 
chromatography (0-2% Et2O/CH2Cl2) yielded rac-
(3aS,4aS,8aR,9aS)-4-((E)-2-(5-(3-90 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione as a 
mixture of isomers. Purification by preparative TLC (0-2% 
Et2O/CH2Cl2) yielded (3aS*,4R*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-95 
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (14) 
(47.3 mg, 0.10 mmol, 49%) and (3aS*,4S*,4aS*,8aR*,9aS*)-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (15) 
(24.5 mg, 0.05 mmol, 26%) as white solids. Data for 100 
(3aS*,4R*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (14): 
1H NMR (600 MHz, CDCl3) δ 8.82 (1H, s, CHN), 7.88 (1H, dd, J 
= 7.9, 2.3, CHCCHN), 7.82 (1H, s, CHCCF3), 7.77 (1H, d, J = 105 
7.9, CHCCHCCF3), 7.67 (1H, d, J = 7.5, CHCHCCF3), 7.62 (1H, 
t, J = 7.5, CHCHCCF3), 7.34 (1H, d, J = 8.3, CHCN), 7.08 (1H, 
dd, J = 15.4, 9.8, C4HCHCHPyr), 6.65 (1H, d, J = 15.1, 
C4HCHCHPyr), 4.47 (1H, t, J = 8.5, C3HH), 4.11 (1H, t, J = 9.8, 
C3HH), 3.61 (1H, d, J = 9.0, C9aH), 3.23 (1H, ddd, J = 9.8, 9.0, 110 
8.5, C3aH), 2.60 (1H, dd, J = 9.8, 3.6, C4H), 2.42 (1H, td, J = 
12.2, 3.6, C8aH), 2.07-2.02 (1H, m, C8HH), 1.91 (1H, tt, J = 12.2, 
3.6, C4aH), 1.83-1.78 (1H, m, C7HH), 1.78-1.73 (1H, m, C6HH), 
1.72-1.67 (1H, m, C5HH), 1.48-1.40 (2H, m, C8HH), 1.40-1.34 
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(1H, m, C5HH), 1.23-1.15 (2H, m, C6HH & C7HH); 13C NMR 
(150 MHz, CDCl3) δ 203.8 (C
9O), 171.6 (C1O), 154.0 (CN), 
148.2 (CHN), 138.4 (CCHCCF3), 135.3 (CHCCHN), 134.2 
(CCHN), 132.7 (C4HCHCHPyr), 132.4 (C4HCHCHPyr), 131.8 
(q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 5 
125.0 (q, J = 3.6, CCHCCF3), 123.8 (q, J = 3.6, CHCHCCF3), 
124.1 (d, J = 271.7, CF3), 122.3 (CHCN), 70.0 (C
3H2), 52.5 
(C9aH), 48.5 (C8aH), 43.5 (C3aH), 42.1 (C4H), 41.6 (C4aH), 31.7 
(C5H2), 25.8 (C
8H2), 25.5 (C
6H2), 25.0 (C
7H2); IR (thin film) 
2930 (C-H), 2855 (C-H), 1784 (C=O), 1708 (C=O), 1478, 1440, 10 
1335, 1164, 1124, 1018, 755 cm-1; m/z (ES+) 456 (100%, 
[M+H]+); HRMS (ES-) calcd for C26H23NO3F3 [M-H]
+ 454.1631, 
observed 454.1630. Chiral column purification (40% 
EtOH/Heptane, f=30ml/min, Column 30mm x 25cm Chiralcel 
OJ-H) gave (+)-(3aS,4R,4aS,8aR,9aS)-4-((E)-2-(5-(3-15 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((+)-14) with an [α]D
25 = +13.2 (MeOH) and 
(-)-(3aS,4R,4aS,8aR,9aS)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-20 
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((-)-14) with an [α]D
25 = -13.4 (MeOH). Data for 
(3aS*,4S*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (15): 25 
1H NMR (600 MHz, CDCl3) δ 8.79 (1H, d, J = 2.3, CHN), 7.87 
(1H, dd, J = 8.1, 2.3, CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 
(1H, d, J = 7.5, CHCCHCCF3), 7.67 (1H, d, J = 7.5, 
CHCHCCF3), 7.61 (1H, t, J = 7.5, CHCHCCF3), 7.32 (1H, d, J = 
8.3, CHCN), 6.70 (1H, d, J = 15.4, C4HCHCHPyr), 6.49 (1H, dd, 30 
J = 15.4, 9.8, C4HCHCHPyr), 4.43 (1H, dd, J = 9.0, 8.3, C3HH), 
4.15 (1H, dd, J = 11.7, 9.0, C3HH), 3.51 (1H, d, J = 8.7, C9aH), 
3.32 (1H, dddd, J = 11.7, 8.7, 8.3, 5.6, C3aH), 2.87 (1H, ddd, J = 
11.3, 9.8, 5.6, C4H), 2.21 (1H, td, J = 11.7, 3.0, C8aH), 2.00-1.93 
(2H, m, C5HH & C8HH), 1.87-1.82 (1H, m, C7HH), 1.75 (2H, qd, 35 
J = 11.3, 3.4, C4aH & C6HH), 1.49-1.40 (1H, m, C8HH), 1.28-
1.15 (2H, m, C6HH & C7HH), 1.13-1.05 (1H, m, C5HH); 13C 
NMR (150 MHz, CDCl3) δ 203.8 (C
9O), 171.7 (C1O), 153.9 
(CN), 148.2 (CHN), 138.4 (CCHCCF3), 135.2 (CHCCHN), 134.2 
(CCHN), 133.2 (C4HCHCHPyr), 132.4 (C4HCHCHPyr), 131.8 40 
(q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 
125.0 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 
124.7 (d, J = 272.0, CF3), 122.0 (CHCN), 68.2 (C
3H2), 54.7 
(C9aH), 52.9 (C8aH), 45.3 (C4H), 44.6 (C3aH), 42.9 (C4aH), 33.0 
(C5H2), 25.2 (C
8H2), 24.9 (C
6H2), 24.8 (C
7H2); IR (thin film) 45 
2923 (C-H), 2853 (C-H), 1782 (C=O), 1703 (C=O), 1333, 1160, 
1119, 1074, 1010, 801, 699 cm-1; m/z (ES+) 456 (100%, 
[M+H]+); HRMS (ES-) calcd for C26H23NO3F3 [M-H]
+ 454.1616, 
observed 454.1630. Chiral column purification (50% 
EtOH/Heptane, f=25ml/min, Column 22.1mm x 25cm (R;R) 50 
Whelk O-1) gave (+)-(3aS,4S,4aS,8aR,9aS)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((+)-15) with an [α]D
25 = +30.4 (MeOH) and 
(-)-(3aS,4S,4aS,8aR,9aS)-4-((E)-2-(5-(3-55 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((-)-15) with an [α]D
25 = -31.6 (MeOH). 
 
(3aS*,4R*,4aS*,8aS*,9aS*)-1,9-60 
Dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid 
TFA (3.00 mL, 38.9 mmol) was added to a stirred solution of 
(3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (12) (1.09 
g, 3.53 mmol) in CH2Cl2 (6 mL) at 0 °C, under N2. The reaction 65 
mixture was stirred at 20 °C for 16 h before being concentrated in 
vacuo. The residue was azeotroped with toluene (25 mL) to yield 
a crude pink solid. Purification by trituration (CH2Cl2) yielded 
(3aS*,4R*,4aS*,8aS*,9aS*)-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylic acid (441 mg, 1.75 mmol, 49%) as a white 70 
solid; 1H NMR (600 MHz, CDCl3) δ 4.33 (1H, d, J = 9.8, C
3HH), 
4.27 (1H, dd, J = 9.8, 4.5, C3HH), 3.55 (1H, d, J = 7.6, C9aH), 
3.22 (1H, ddd, J = 11.5, 7.6, 4.5, C3aH), 2.57 (1H, t, J = 11.5, 
C4H), 2.19-2.12 (1H, m, C8HH), 2.06- 2.01 (1H, m, C8aH), 1.89-
1.82 (2H, m, C6HH & C7HH), 1.81-1.73 (2H, m, C5HH & C4aH), 75 
1.26-1.18 (4H, m, C5HH, C6HH, C7HH & C8HH); 13C NMR (150 
MHz, CDCl3) δ 201.5 (C
9O), 177.5 (COOH), 171.2 (C1O), 70.6 
(C3H2), 53.2 (C
9aH), 51.1 (C4H), 49.9 (C8aH), 42.5 (C3aH), 42.4 
(C4aH), 31.8 (C5H2), 25.1 (C
8H2), 25.0 (C
6H2), 24.7 (C
7H2); IR 
(thin film) 2930 (C-H), 2869 (C-H), 1779 (C=O), 1705 (C=O), 80 
1171, 1166, 1018 cm-1; m/z (ES+) 253 (100%, [M+H]+); HRMS 
(EI) calcd for C13H16O5 [M]
+ 252.0992, observed 252.0982. 
 
(3aR*,4R*,4aS*,8aS*,9aS*)-S-ethyl 1,9-
Dioxododecahydronaphtho[2,3-c]furan-4-carbothioate 85 
EDCl (502 mg, 2.62 mmol) was added to a stirred solution of 
(3aS*,4R*,4aS*,8aS*,9aS*)-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylic acid (440 mg, 1.74 mmol), ethanethiol (0.52 
mL, 6.98 mmol) and DMAP (21.3 mg, 0.17 mmol) in CH2Cl2 (20 
mL) under N2. The reaction mixture was stirred at 20 °C for 2 h 90 
and then quenched with sat. aq. NH4Cl (10 mL). An extraction 
into CH2Cl2 (10 mL) was done and the organic layer was dried 
(hydrophobic frit) and concentrated in vacuo to yield 
(3aR*,4R*,4aS*,8aS*,9aS*)-S-ethyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (482 mg, 95 
1.62 mmol, 93%) as an off-white solid; 1H NMR (600 MHz, 
CDCl3) δ 4.38 (1H, d, J = 9.6, C
3HH), 4.18 (1H, dd, J = 9.6, 4.7, 
C3HH), 3.51 (1H, d, J = 7.5, C9aH), 3.21 (1H, ddd, J = 11.6, 7.4, 
4.7, C3aH), 3.02-2.89 (2H, m, CH2CH3), 2.70 (1H, t, J = 11.1, 
C4H), 2.15-2.10 (1H, m, C8HH), 2.02 (1H, td, J = 11.2, 3.2, 100 
C8aH), 1.85-1.69 (4H, m, C4aH, C5HH, C6HH & C7HH), 1.30-
1.27 (3H, m, CH2CH3), 1.27-1.09 (4H, m, C
5HH, C6HH, C7HH & 
C8HH); IR (thin film) 2930 (C-H), 2876 (C-H), 1783 (C=O), 
1706 (C=O), 1671 (C=O), 1448, 1362, 1203, 1137, 1012, 981, 
896 cm-1; m/z (ES+) 297 (100%, [M+H]+); HRMS (EI) calcd for 105 
C15H20O4S [M]
+ 296.1077, observed 296.1076. 
 
rac-(3aS,4aR,8aS,9aS)-1,9-Dioxododecahydronaphtho[2,3-
c]furan-4-carbaldehyde 
Triethylsilane (1.02 mL, 6.41 mmol) was added to a stirred 110 
solution of (3aR*,4R*,4aS*,8aS*,9aS*)-S-ethyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (475 mg, 
1.60 mmol), palladium on carbon (10%) (171 mg, 1.60 mmol) 
and MgSO4 (to dry) in anhydrous, degassed acetone (25 mL) 
under N2. The reaction mixture was stirred at 20 °C for 16 h 115 
before being filtered through celite and the filtrate concentrated in 
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vacuo. Purification by flash column chromatography (0-100% 
EtOAc/cyclohexane) gave partial racemisation at C4 to yield rac-
(3aS,4aR,8aS,9aS)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carbaldehyde (4S:4R; 1:6) (130 mg, 0.55 mmol, 34%) as a 
colourless oil; 1H NMR (600 MHz, CDCl3) δ 9.90-9.89 (1H, m, 5 
4S-CHO), 9.83 (1H, d, J = 2.8, 4R-CHO), 4.26 (1H, dd, J = 9.8, 
4.7, 4R-C3HH), 4.20 (1H, d, J = 9.6, 4R-C3HH), 3.56 (1H, d, J = 
7.8, 4R-C9aH), 3.22 (1H, ddd, J = 11.6, 7.5, 4.5, 4R-C3aH), 2.57 
(1H, td, J = 11.4, 2.9, 4R-C4H), 2.18-2.11 (2H, m, 4R-C8HH & 
4R-C8aH), 2.04-1.97 (2H, m, 4R-C6HH & 4R-C7HH), 1.89-1.77 10 
(2H, m, 4R-C5HH & 4R-C4aH), 1.40-1.35 (1H, m, 4R-C8HH), 
1.32-1.19 (3H, m, 4R-C5HH, 4R-C6HH & 4R-C7HH); 13C NMR 
(150 MHz, CDCl3) δ 201.6 (4R-C
9O), 201.3 (4R-CHO), 168.7 
(4R-C1O), 70.4 (4R-C3H2), 54.8 (4R-C
4H), 52.9 (4R-C9aH), 51.1 
(4R-C8aH), 41.8 (4R-C4aH), 39.1 (4R-C3aH), 31.7 (4R-C5H2), 24.9 15 
(4R-C8H2 & 4R-C
6H2), 24.5 (4R-C
7H2), 19.1 (4S-C
3HCH3); IR 
(thin film) 2927 (C-H), 2855 (C-H), 1770 (C=O), 1713 (C=O), 
1125, 730 cm-1; m/z (ES+) 237 (100%, [M+H]+); HRMS (EI) 
calcd for C13H16O4 [M]
+ 236.1043, observed 236.1049. 
 20 
(3aS*,4R*,4aR*,8aS*,9aS*)-4-((E)-2-(5-(3-
(Trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
(16) 
n-BuLi (2.7 M in heptanes) (0.25 mL, 0.66 mmol) was added 25 
dropwise to a stirred solution of diethyl (5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (7) (226 
mg, 0.60 mmol) in anhydrous 2-MeTHF (10 mL) at 0 °C, under 
N2. The solution was stirred at 0 °C for 10 min before a solution 
of rac-(3aS,4aR,8aS,9aS)-1,9-dioxododecahydronaphtho[2,3-30 
c]furan-4-carbaldehyde (130 mg, 0.55 mmol) in anhydrous 2-
MeTHF (10 mL) was added. The reaction mixture was stirred at 0 
°C for a further 1 h and then quenched with sat. aq. NH4Cl (5 
mL). An extraction into EtOAc (10 mL) was done and the 
organic phase was washed with brine (5 mL), dried (hydrophobic 35 
frit) and concentrated in vacuo to yield a crude yellow gum. 
Purification by automated column chromatography (0-100% 
EtOAc/cyclohexane) yielded (3aS*,4R*,4aR*,8aS*,9aS*)-4-((E)-
2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (76.0 40 
mg, 0.17 mmol, 25 %) as a yellow glassy solid; 1H NMR (600 
MHz, CDCl3) δ 8.82 (1H, d, J = 2.0, CHN), 7.90 (1H, dd, J = 8.1, 
2.4, CHCCHN), 7.83 (1H, s, CHCCF3), 7.78 (1H, d, J = 7.6, 
CHCCHCCF3), 7.69 (1H, d, J = 7.8, CHCHCCF3), 7.63 (1H, t, J 
= 7.6, CHCHCCF3), 7.36 (1H, dd, J = 8.2, 0.6, CHCN), 6.70 (1H, 45 
d, J = 15.4, C4HCHCHPyr), 6.56 (1H, dd, J = 15.4, 9.4, 
C4HCHCHPyr), 4.37 (1H, d, J = 9.4, C3HH), 4.20 (1H, dd, J = 
9.4, 4.8, C3HH), 3.58 (1H, d, J = 7.4, C9aH), 2.85 (1H, ddd, J = 
11.1, 7.4, 4.8, C3aH), 2.34 (1H, td, J = 11.1, 9.4, C4H), 2.20-2.08 
(1H, m, C8aH & C8HH), 2.02-1.94 (1H, m, C5HH), 1.86-1.66 50 
(2H, m, C6HH & C7HH), 1.56 (1H, qd, J = 11.2, 3.4, C4aH), 1.34-
1.00 (4H, m, C5HH, C6HH,  C7HH & C8HH); 13C NMR (150 
MHz, CDCl3) δ 203.0 (C
9O), 172.1 (C1O), 152.6 (CN), 147.8 
(CHN), 138.2 (CCHCCF3), 134.7 (CHCCHN), 134.4 (CCHN), 
134.3 (C4HCHCHPyr), 131.9 (C4HCHCHPyr), 131.8 (q, J = 32.1, 55 
CCF3), 130.3 (CHCCHCCF3), 129.9 (CHCHCCF3), 125.1 (q, J = 
3.6, CHCHCCF3), 123.9 (q, J = 3.6, CCHCCF3), 124.0 (d, J = 
272.0, CF3), 122.5 (CHCN), 70.5 (C
3H2), 53.9 (C
9aH), 52.0 
(C8aH), 48.2 (C4H), 44.5 (C3aH), 44.4 (C4aH), 32.7 (C5H2), 25.4 
(C8H2), 25.3 (C
6H2), 24.9 (C
7H2); IR (thin film) 2930 (C-H), 60 
2858 (C-H), 1772 (C=O), 1706 (C=O), 1335, 1167, 1119, 1072, 
998, 971, 810 cm-1; m/z (ES+) 455 (100%, [M+H]+); HRMS (EI) 
calcd for C26H24O3F3N [M+H]
+ 455.17028, observed 455.17029. 
Chiral column purification (70% EtOH/Heptane, f=20ml/min, 
Column 30mm x 25cm Chiralpak AD-H) gave 65 
(+)-(3aS,4R,4aR,8aS,9aS)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((+)-16) with an [α]D
25 = +31.4 (MeOH) and 
(-)-(3aS,4R,4aR,8aS,9aS)-4-((E)-2-(5-(3-70 
(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione 
((-)-16) with an [α]D
25 = -31.3 (MeOH). 
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